Metachronous bilateral breast metastases of a lung neuroendocrine tumor: A case report

MIE KOTAKE1, HISAO IMAI1, RYOICHI ONOZATO2, ATSUSHI FUJITA2, TOMOMI FUJISAWA3, YOSHIMASA NAKAZATO4, MISA IJIMA5, YASUHIRO YANAGITA3, TAKESHI HISADA6 and KOICHI MINATO1

Divisions of 1Respiratory Medicine, 2Thoracic Surgery and 3Breast Oncology, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550; 4Department of Diagnostic Pathology, Dokkyo Medical University, Mibu, Tochigi 321-0293; 5Pathology and Clinical Laboratories, Gunma Prefectural Cancer Center, Ota, Gunma 373-8550; 6Gunma University Graduate School of Health Science, Maebashi, Gunma 371-8514, Japan

Received February 18, 2019; Accepted June 2, 2020

DOI: 10.3892/mco.2020.2123

Abstract. Breast metastases of primary lung neuroendocrine tumors are rarely reported. The current report presents the case of a 41-year old female with no history of smoking who initially underwent surgery for a breast fibroadenoma, during which a neuroendocrine tumor of the right lung was detected via chest X-ray. The patient underwent surgery for the tumor and developed right breast nodules after adjuvant chemotherapy. Histological and immunohistochemical examinations of biopsies from these nodules indicated breast metastasis of the primary lung neuroendocrine tumor. The patient underwent mastectomy of the right breast but subsequently developed metastases in the left breast, for which local radiotherapy was administered. The observed metachronous bilateral breast metastases indicated that the contralateral breast should be considered during an investigation of metastasis.

Introduction

Lung cancer is the most common cause of cancer death worldwide (1). Localized stage of lung cancer represents approximately 15% of lung cancer (2). Estimated new case of non-small cell lung cancer (NSCLC) in the United States is approximately 22,800, with an estimated 13,500 death each year by NSCLC (2). After resection for early-stage NSCLC, 20% of patients developed recurrences (3). NSCLC patients with postoperative recurrence had poor prognosis. Survivals after recurrence were 13% at 5 years in patients who underwent resection for NSCLC (4). The most common sites of lung cancer metastases are the brain, bone, liver, and adrenal glands (5). Previous study showed that the first recurrent site was distant in 78% of patients and patients with distant recurrence had a shorter postrecurrrent survival than those with local recurrence (6). There are only few reports that have demonstrated breast metastases of primary lung neuroendocrine tumors (7-10). Here, we report a case of a female patient who developed metachronous bilateral breast metastases of a lung neuroendocrine tumor.

Case report

A 41-year-old woman with no history of smoking underwent surgery for a breast fibroadenoma. An abnormal shadow was observed on a chest X-ray, and subsequent chest computed tomography (CT) revealed nodules on the right lung (Fig. 1). 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) revealed increased tracer uptake that was highly suggestive of lung cancer, with no evidence of metastasis. The patient underwent right lower and middle lobectomy, and immunohistochemistry revealed that the tumor cells were positive for transcription termination factor-1 (TTF-1), CD56, chromogranin A, and synaptophysin (Fig. 2). Additionally, 25.7% of the tumor cells expressed the proliferation marker Ki67. A pathological analysis led to a diagnosis of neuroendocrine tumor. A regular medical follow-up of the surgical outcomes for breast fibroadenoma revealed nodules in the right breast 3 months after adjuvant chemotherapy (Fig. 3), which were subsequently biopsied. Histological analyses of hematoxylin and eosin (H&E)-stained, paraffin-embedded biopsy sections indicated carcinoma, and positive immunohistochemical staining for CD56, chromogranin A, and synaptophysin confirmed a neuroendocrine origin (Fig. 2). Accordingly, a diagnosis of breast metastasis of primary lung neuroendocrine tumor was made based on cytological and immunohistochemical similarities between the primary and metastatic lesions. The patient underwent mastectomy of the right breast after 18F-FDG-PET/CT revealed no areas of increased tracer uptake. Subsequently, she developed metastases in the left breast, lung, lymph node, and peritoneum at 2 months post-mastectomy (Fig. 4). Systemic chemotherapy and local radiotherapy to the left breast were administered. The patient remained alive 6 months later, with no evidence of a bilateral breast recurrence.

Correspondence to: Dr Mie Kotake, Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1 Takahayashinishi, Ota, Gunma 373-8550, Japan
E-mail: mi0702012@gunma-u.ac.jp

Key words: lung neuroendocrine tumor, metastatic cancer, breast metastases
Breast metastasis of lung cancer is rarely reported. Particularly, a few reports have described breast metastasis from lung neuroendocrine tumors, which account for approximately 3% of lung cancers in surgical series (7-11). Overall, breast metastases of all extramammary malignancies are very rare, accounting for 0.4-1.3% of all mammary malignancies (12,13). These generally arise from primary hematological malignancies, melanoma, rhabdomyosarcoma, lung tumors, renal cell carcinoma, thyroid and cervical carcinomas, intestinal carcinoid, epidermoid carcinoma of the head and neck, and leiomyosarcoma (12,13).

Previous reports have demonstrated the benefits of local therapy for a subset of patients with stage IV non-small cell lung cancer and a small number of metastases (14,15). Vaughan et al described three cases of breast metastases of neuroendocrine tumors of the lung, of which two were treated with surgery. One patient developed a breast metastasis 38 months after her original diagnosis, for which she underwent a lumpectomy and remained free of a breast recurrence 7 months later. The second patient presented with a breast metastasis 8 months after her original diagnosis and underwent an excisional biopsy. She subsequently developed another breast metastasis 4 months after the first excision and underwent radiation treatment (10). The patient in our case achieved good local control with a right mastectomy, but subsequently developed metastases in the left breast. However, she maintained good local control of the left-sided breast nodules after radiation therapy.

A search of the PubMed database between 2007 and 2017 identified 13 cases of breast metastases from neuroendocrine tumors of the lung (Table I). Despite the rarity of this condition, the possibility of metastasis to the breast from a lung neuroendocrine tumor should be considered in the differential diagnosis of a primary mammary carcinoma in patients postoperatively discovered to have a breast lesion. One of 13 patients had bilateral breast metastases during the initial diagnostic evaluation (Table I). This finding and our observa-
tion of metachronous bilateral breast metastases in the present case leads us to suggest that the contralateral breast should be considered in an investigation of metastasis.

In summary, we report herein a rare case of a patient with metachronous bilateral breast metastases of a primary lung neuroendocrine tumor. The present case suggests that local therapy provides good control of these metastatic lesions.

Acknowledgements

The authors would like to thank Dr Takeshi Kawakami and Dr Hiroyuki Horikoshi (Division of Diagnostic Radiology of Gunma Prefectural Cancer Center) for helping with figure preparation. The authors would also like to thank Dr Sakae Fujimoto (Division of Respiratory Medicine of Gunma Prefectural Cancer Center) for his assistance in preparing this manuscript.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

MK, HI and KM designed the current study. MK, HI, RO, AF, TF, YY, YN, MI and KM acquired and analyzed the data. YN and MI performed histological examinations of the tumor specimens. MK and HI drafted the manuscript and constructed the figures. TH advised the study and analyzed the data. All the authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Written informed consent was obtained from the patient for publication.

Competing interests

The authors declare that they have no competing interests.

References


Table I. Characteristics of previously reported cases of breast metastases from lung neuroendocrine tumors.

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age, years/sex</th>
<th>Interval, from NET diagnosis to breast tumor (months)</th>
<th>Vital status</th>
<th>Secondary survival (months)*</th>
<th>Breast laterality</th>
<th>Breast surgery/radiotherapy</th>
<th>Chemotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (9)</td>
<td>44/F</td>
<td>0</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Mastectomy</td>
<td>NR</td>
</tr>
<tr>
<td>2 (9)</td>
<td>60/F</td>
<td>22</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>3 (9)</td>
<td>44/F</td>
<td>37</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>4 (9)</td>
<td>28/F</td>
<td>87</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>5 (9)</td>
<td>42/F</td>
<td>69</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>6 (9)</td>
<td>62/F</td>
<td>20</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>7 (9)</td>
<td>45/F</td>
<td>36</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Lumpectomy</td>
<td>NR</td>
</tr>
<tr>
<td>8 (9)</td>
<td>72/F</td>
<td>20</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>No performed</td>
<td>NR</td>
</tr>
<tr>
<td>9 (10)</td>
<td>30/F</td>
<td>38</td>
<td>Alive</td>
<td>7</td>
<td>Left</td>
<td>Lumpectomy, radiotherapy</td>
<td>NR</td>
</tr>
<tr>
<td>10 (10)</td>
<td>35/F</td>
<td>8</td>
<td>Alive</td>
<td>9</td>
<td>Bilateral</td>
<td>No performed</td>
<td>NR</td>
</tr>
<tr>
<td>11 (10)</td>
<td>28/F</td>
<td>8</td>
<td>Dead</td>
<td>17</td>
<td>Right</td>
<td>Lumpectomy, radiotherapy</td>
<td>NR</td>
</tr>
<tr>
<td>12 (8)</td>
<td>49/F</td>
<td>6</td>
<td>Dead</td>
<td>7</td>
<td>Left</td>
<td>Radiotherapy, not performed</td>
<td>NR</td>
</tr>
<tr>
<td>13 (7)</td>
<td>59/F</td>
<td>0</td>
<td>Dead</td>
<td>NR</td>
<td>Right</td>
<td>Not performed</td>
<td>Cisplatin + etoposide, topotecan, perfomed</td>
</tr>
<tr>
<td>The current case</td>
<td>41/F</td>
<td>12</td>
<td>Alive</td>
<td>18</td>
<td>Bilateral</td>
<td>Mastectomy, radiotherapy</td>
<td>NR</td>
</tr>
</tbody>
</table>

*Time interval between the diagnosis of breast metastasis and death or study follow-up. NR, not reported; F, female.


